1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Classification of GABAB Receptor Agonists by Type
  • 1.3.1 Overview: Global GABAB Receptor Agonists Market Size by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 Global GABAB Receptor Agonists Consumption Value Market Share by Type in 2025
  • 1.3.3 Baclofen
  • 1.3.4 Sodium Oxybate
  • 1.3.5 Mixed Oxybate Salts
• 1.4 Classification of GABAB Receptor Agonists by Dosage Form
  • 1.4.1 Overview: Global GABAB Receptor Agonists Market Size by Dosage Form: 2021 Versus 2025 Versus 2032
  • 1.4.2 Global GABAB Receptor Agonists Consumption Value Market Share by Dosage Form in 2025
  • 1.4.3 Tablets
  • 1.4.4 Oral Solutions
  • 1.4.5 Others
• 1.5 Classification of GABAB Receptor Agonists by Product Status
  • 1.5.1 Overview: Global GABAB Receptor Agonists Market Size by Product Status: 2021 Versus 2025 Versus 2032
  • 1.5.2 Global GABAB Receptor Agonists Consumption Value Market Share by Product Status in 2025
  • 1.5.3 Originator Drugs
  • 1.5.4 Generic Drugs
• 1.6 Global GABAB Receptor Agonists Market by Application
  • 1.6.1 Overview: Global GABAB Receptor Agonists Market Size by Application: 2021 Versus 2025 Versus 2032
  • 1.6.2 Hospital
  • 1.6.3 Clinic
  • 1.6.4 Other
• 1.7 Global GABAB Receptor Agonists Market Size & Forecast
• 1.8 Global GABAB Receptor Agonists Market Size and Forecast by Region
  • 1.8.1 Global GABAB Receptor Agonists Market Size by Region: 2021 VS 2025 VS 2032
  • 1.8.2 Global GABAB Receptor Agonists Market Size by Region, (2021-2032)
  • 1.8.3 North America GABAB Receptor Agonists Market Size and Prospect (2021-2032)
  • 1.8.4 Europe GABAB Receptor Agonists Market Size and Prospect (2021-2032)
  • 1.8.5 Asia-Pacific GABAB Receptor Agonists Market Size and Prospect (2021-2032)
  • 1.8.6 South America GABAB Receptor Agonists Market Size and Prospect (2021-2032)
  • 1.8.7 Middle East & Africa GABAB Receptor Agonists Market Size and Prospect (2021-2032)

2 Company Profiles

• 2.1 Jazz Pharmaceuticals
  • 2.1.1 Jazz Pharmaceuticals Details
  • 2.1.2 Jazz Pharmaceuticals Major Business
  • 2.1.3 Jazz Pharmaceuticals GABAB Receptor Agonists Product and Solutions
  • 2.1.4 Jazz Pharmaceuticals GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Jazz Pharmaceuticals Recent Developments and Future Plans
• 2.2 Alkermes
  • 2.2.1 Alkermes Details
  • 2.2.2 Alkermes Major Business
  • 2.2.3 Alkermes GABAB Receptor Agonists Product and Solutions
  • 2.2.4 Alkermes GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 Alkermes Recent Developments and Future Plans
• 2.3 Hikma Pharmaceuticals
  • 2.3.1 Hikma Pharmaceuticals Details
  • 2.3.2 Hikma Pharmaceuticals Major Business
  • 2.3.3 Hikma Pharmaceuticals GABAB Receptor Agonists Product and Solutions
  • 2.3.4 Hikma Pharmaceuticals GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.3.5 Hikma Pharmaceuticals Recent Developments and Future Plans
• 2.4 Amneal Pharmaceuticals
  • 2.4.1 Amneal Pharmaceuticals Details
  • 2.4.2 Amneal Pharmaceuticals Major Business
  • 2.4.3 Amneal Pharmaceuticals GABAB Receptor Agonists Product and Solutions
  • 2.4.4 Amneal Pharmaceuticals GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.4.5 Amneal Pharmaceuticals Recent Developments and Future Plans
• 2.5 Azurity Pharmaceuticals
  • 2.5.1 Azurity Pharmaceuticals Details
  • 2.5.2 Azurity Pharmaceuticals Major Business
  • 2.5.3 Azurity Pharmaceuticals GABAB Receptor Agonists Product and Solutions
  • 2.5.4 Azurity Pharmaceuticals GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.5.5 Azurity Pharmaceuticals Recent Developments and Future Plans
• 2.6 Piramal Pharma
  • 2.6.1 Piramal Pharma Details
  • 2.6.2 Piramal Pharma Major Business
  • 2.6.3 Piramal Pharma GABAB Receptor Agonists Product and Solutions
  • 2.6.4 Piramal Pharma GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.6.5 Piramal Pharma Recent Developments and Future Plans
• 2.7 ANI Pharmaceuticals
  • 2.7.1 ANI Pharmaceuticals Details
  • 2.7.2 ANI Pharmaceuticals Major Business
  • 2.7.3 ANI Pharmaceuticals GABAB Receptor Agonists Product and Solutions
  • 2.7.4 ANI Pharmaceuticals GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.7.5 ANI Pharmaceuticals Recent Developments and Future Plans
• 2.8 Teva Pharmaceutical Industries
  • 2.8.1 Teva Pharmaceutical Industries Details
  • 2.8.2 Teva Pharmaceutical Industries Major Business
  • 2.8.3 Teva Pharmaceutical Industries GABAB Receptor Agonists Product and Solutions
  • 2.8.4 Teva Pharmaceutical Industries GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.8.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
• 2.9 Viatris
  • 2.9.1 Viatris Details
  • 2.9.2 Viatris Major Business
  • 2.9.3 Viatris GABAB Receptor Agonists Product and Solutions
  • 2.9.4 Viatris GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.9.5 Viatris Recent Developments and Future Plans
• 2.10 Sandoz
  • 2.10.1 Sandoz Details
  • 2.10.2 Sandoz Major Business
  • 2.10.3 Sandoz GABAB Receptor Agonists Product and Solutions
  • 2.10.4 Sandoz GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.10.5 Sandoz Recent Developments and Future Plans
• 2.11 Sun Pharmaceutical Industries
  • 2.11.1 Sun Pharmaceutical Industries Details
  • 2.11.2 Sun Pharmaceutical Industries Major Business
  • 2.11.3 Sun Pharmaceutical Industries GABAB Receptor Agonists Product and Solutions
  • 2.11.4 Sun Pharmaceutical Industries GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.11.5 Sun Pharmaceutical Industries Recent Developments and Future Plans
• 2.12 Aurobindo Pharma
  • 2.12.1 Aurobindo Pharma Details
  • 2.12.2 Aurobindo Pharma Major Business
  • 2.12.3 Aurobindo Pharma GABAB Receptor Agonists Product and Solutions
  • 2.12.4 Aurobindo Pharma GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.12.5 Aurobindo Pharma Recent Developments and Future Plans
• 2.13 Tsly Pharmaceutical Group
  • 2.13.1 Tsly Pharmaceutical Group Details
  • 2.13.2 Tsly Pharmaceutical Group Major Business
  • 2.13.3 Tsly Pharmaceutical Group GABAB Receptor Agonists Product and Solutions
  • 2.13.4 Tsly Pharmaceutical Group GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.13.5 Tsly Pharmaceutical Group Recent Developments and Future Plans
• 2.14 Hemony Pharmaceutical
  • 2.14.1 Hemony Pharmaceutical Details
  • 2.14.2 Hemony Pharmaceutical Major Business
  • 2.14.3 Hemony Pharmaceutical GABAB Receptor Agonists Product and Solutions
  • 2.14.4 Hemony Pharmaceutical GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.14.5 Hemony Pharmaceutical Recent Developments and Future Plans
• 2.15 Fuan Pharmaceutical Group
  • 2.15.1 Fuan Pharmaceutical Group Details
  • 2.15.2 Fuan Pharmaceutical Group Major Business
  • 2.15.3 Fuan Pharmaceutical Group GABAB Receptor Agonists Product and Solutions
  • 2.15.4 Fuan Pharmaceutical Group GABAB Receptor Agonists Revenue, Gross Margin and Market Share (2021-2026)
  • 2.15.5 Fuan Pharmaceutical Group Recent Developments and Future Plans

3 Market Competition, by Players

• 3.1 Global GABAB Receptor Agonists Revenue and Share by Players (2021-2026)
• 3.2 Market Share Analysis (2025)
  • 3.2.1 Market Share of GABAB Receptor Agonists by Company Revenue
  • 3.2.2 Top 3 GABAB Receptor Agonists Players Market Share in 2025
  • 3.2.3 Top 6 GABAB Receptor Agonists Players Market Share in 2025
• 3.3 GABAB Receptor Agonists Market: Overall Company Footprint Analysis
  • 3.3.1 GABAB Receptor Agonists Market: Region Footprint
  • 3.3.2 GABAB Receptor Agonists Market: Company Product Type Footprint
  • 3.3.3 GABAB Receptor Agonists Market: Company Product Application Footprint
• 3.4 New Market Entrants and Barriers to Market Entry
• 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

• 4.1 Global GABAB Receptor Agonists Consumption Value and Market Share by Type (2021-2026)
• 4.2 Global GABAB Receptor Agonists Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

• 5.1 Global GABAB Receptor Agonists Consumption Value Market Share by Application (2021-2026)
• 5.2 Global GABAB Receptor Agonists Market Forecast by Application (2027-2032)

6 North America

• 6.1 North America GABAB Receptor Agonists Consumption Value by Type (2021-2032)
• 6.2 North America GABAB Receptor Agonists Market Size by Application (2021-2032)
• 6.3 North America GABAB Receptor Agonists Market Size by Country
  • 6.3.1 North America GABAB Receptor Agonists Consumption Value by Country (2021-2032)
  • 6.3.2 United States GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 6.3.3 Canada GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 6.3.4 Mexico GABAB Receptor Agonists Market Size and Forecast (2021-2032)

7 Europe

• 7.1 Europe GABAB Receptor Agonists Consumption Value by Type (2021-2032)
• 7.2 Europe GABAB Receptor Agonists Consumption Value by Application (2021-2032)
• 7.3 Europe GABAB Receptor Agonists Market Size by Country
  • 7.3.1 Europe GABAB Receptor Agonists Consumption Value by Country (2021-2032)
  • 7.3.2 Germany GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 7.3.3 France GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 7.3.4 United Kingdom GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 7.3.5 Russia GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 7.3.6 Italy GABAB Receptor Agonists Market Size and Forecast (2021-2032)

8 Asia-Pacific

• 8.1 Asia-Pacific GABAB Receptor Agonists Consumption Value by Type (2021-2032)
• 8.2 Asia-Pacific GABAB Receptor Agonists Consumption Value by Application (2021-2032)
• 8.3 Asia-Pacific GABAB Receptor Agonists Market Size by Region
  • 8.3.1 Asia-Pacific GABAB Receptor Agonists Consumption Value by Region (2021-2032)
  • 8.3.2 China GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 8.3.3 Japan GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 8.3.4 South Korea GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 8.3.5 India GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 8.3.6 Southeast Asia GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 8.3.7 Australia GABAB Receptor Agonists Market Size and Forecast (2021-2032)

9 South America

• 9.1 South America GABAB Receptor Agonists Consumption Value by Type (2021-2032)
• 9.2 South America GABAB Receptor Agonists Consumption Value by Application (2021-2032)
• 9.3 South America GABAB Receptor Agonists Market Size by Country
  • 9.3.1 South America GABAB Receptor Agonists Consumption Value by Country (2021-2032)
  • 9.3.2 Brazil GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 9.3.3 Argentina GABAB Receptor Agonists Market Size and Forecast (2021-2032)

10 Middle East & Africa

• 10.1 Middle East & Africa GABAB Receptor Agonists Consumption Value by Type (2021-2032)
• 10.2 Middle East & Africa GABAB Receptor Agonists Consumption Value by Application (2021-2032)
• 10.3 Middle East & Africa GABAB Receptor Agonists Market Size by Country
  • 10.3.1 Middle East & Africa GABAB Receptor Agonists Consumption Value by Country (2021-2032)
  • 10.3.2 Turkey GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 10.3.3 Saudi Arabia GABAB Receptor Agonists Market Size and Forecast (2021-2032)
  • 10.3.4 UAE GABAB Receptor Agonists Market Size and Forecast (2021-2032)

11 Market Dynamics

• 11.1 GABAB Receptor Agonists Market Drivers
• 11.2 GABAB Receptor Agonists Market Restraints
• 11.3 GABAB Receptor Agonists Trends Analysis
• 11.4 Porters Five Forces Analysis
  • 11.4.1 Threat of New Entrants
  • 11.4.2 Bargaining Power of Suppliers
  • 11.4.3 Bargaining Power of Buyers
  • 11.4.4 Threat of Substitutes
  • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

• 12.1 GABAB Receptor Agonists Industry Chain
• 12.2 GABAB Receptor Agonists Upstream Analysis
• 12.3 GABAB Receptor Agonists Midstream Analysis
• 12.4 GABAB Receptor Agonists Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology
• 14.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global GABAB Receptor Agonists market size was valued at US$ 3334 million in 2025 and is forecast to a readjusted size of US$ 4710 million by 2032 with a CAGR of 5.0% during review period.
GABAB receptor agonists are central nervous system prescription medicines that activate metabotropic GABAB receptors, inhibit presynaptic excitatory neurotransmitter release, and reduce neuronal excitability. Commercial products mainly include baclofen formulations used for spasticity associated with multiple sclerosis, spinal cord injury, and other neurological disorders, together with sodium oxybate and mixed oxybate salt products used for cataplexy, excessive daytime sleepiness in narcolepsy, and idiopathic hypersomnia. Major dosage forms include tablets, oral solutions, oral suspensions, oral granules, intrathecal injections, and extended-release oral suspensions. Upstream inputs mainly include baclofen, sodium oxybate, and mixed oxybate salt active ingredients, together with thickeners, sweeteners, extended-release materials, sterile injectable excipients, pharmaceutical packaging, and intrathecal pump-related consumables. Downstream customers mainly include neurology departments, rehabilitation centers, spinal cord injury centers, sleep medicine centers, specialty pharmacies, hospital pharmacies, and controlled-drug distribution organizations. Competition is relatively intense in standard baclofen tablets, while low-sodium oxybate, extended-release sodium oxybate, differentiated oral formulations, and intrathecal baclofen products retain higher added value, with an overall gross margin generally ranging from approximately 58% to 82%.
From the current market perspective, the GABAB receptor agonist market has a dual structure consisting of high-volume, low-priced baclofen products and high-priced oxybate therapies used in relatively small patient populations. Baclofen is a mature treatment for spasticity and is available as generic tablets, oral liquids, concentrated suspensions, granules, and intrathecal injections. The oxybate segment is concentrated in narcolepsy and idiopathic hypersomnia and is led by a small number of specialty pharmaceutical companies.
Looking ahead, the baclofen segment will increasingly focus on liquid formulations, granules, and intrathecal products for pediatric, elderly, dysphagic, and severe-spasticity patients. Growth in standard tablets will remain limited. Oxybate development will focus on lower-sodium formulations, once-at-bedtime dosing, adherence improvement, and expansion in idiopathic hypersomnia. Sodium burden, nighttime redosing, dosing convenience, and controlled distribution will remain important competitive factors.
Key market drivers include spasticity associated with multiple sclerosis, spinal cord injury, cerebral palsy, stroke, and other central nervous system disorders. Improved diagnosis of narcolepsy and idiopathic hypersomnia, expansion of sleep medicine centers, and greater patient access are supporting demand for oxybate therapies. Low-sodium and extended-release formulations may improve patient conversion and persistence by addressing sodium exposure and nighttime dosing inconvenience.
The main constraints include somnolence, dizziness, muscle weakness, cognitive effects, and severe withdrawal associated with abrupt baclofen discontinuation. Intrathecal therapy requires an implanted pump and specialist management and may be affected by pump or catheter complications. Oxybates are tightly controlled central nervous system depressants associated with abuse, misuse, respiratory depression, and dangerous interactions with alcohol and sedatives. High treatment costs, insurance access, restricted distribution, and generic competition also constrain market growth.
This report is a detailed and comprehensive analysis for global GABAB Receptor Agonists market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global GABAB Receptor Agonists market size and forecasts, in consumption value ($ Million), 2021-2032
Global GABAB Receptor Agonists market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global GABAB Receptor Agonists market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global GABAB Receptor Agonists market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for GABAB Receptor Agonists
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global GABAB Receptor Agonists market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Jazz Pharmaceuticals, Alkermes, Hikma Pharmaceuticals, Amneal Pharmaceuticals, Azurity Pharmaceuticals, Piramal Pharma, ANI Pharmaceuticals, Teva Pharmaceutical Industries, Viatris, Sandoz, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
GABAB Receptor Agonists market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Baclofen
Sodium Oxybate
Mixed Oxybate Salts
Market segment by Dosage Form
Tablets
Oral Solutions
Others
Market segment by Product Status
Originator Drugs
Generic Drugs
Market segment by Application
Hospital
Clinic
Other
Market segment by players, this report covers
Jazz Pharmaceuticals
Alkermes
Hikma Pharmaceuticals
Amneal Pharmaceuticals
Azurity Pharmaceuticals
Piramal Pharma
ANI Pharmaceuticals
Teva Pharmaceutical Industries
Viatris
Sandoz
Sun Pharmaceutical Industries
Aurobindo Pharma
Tsly Pharmaceutical Group
Hemony Pharmaceutical
Fuan Pharmaceutical Group
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe GABAB Receptor Agonists product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of GABAB Receptor Agonists, with revenue, gross margin, and global market share of GABAB Receptor Agonists from 2021 to 2026.
Chapter 3, the GABAB Receptor Agonists competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and GABAB Receptor Agonists market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of GABAB Receptor Agonists.
Chapter 13, to describe GABAB Receptor Agonists research findings and conclusion.